196 related articles for article (PubMed ID: 35469393)
21. Cost-effectiveness analysis of rotavirus vaccination in Argentina.
Urueña A; Pippo T; Betelu MS; Virgilio F; Hernández L; Giglio N; Gentile Á; Diosque M; Vizzotti C
Vaccine; 2015 May; 33 Suppl 1():A126-34. PubMed ID: 25919152
[TBL] [Abstract][Full Text] [Related]
22. [A cost-effectiveness analysis on universal infant rotavirus vaccination strategy in China].
Sun SL; Gao YQ; Yin J; Zhuang GH
Zhonghua Liu Xing Bing Xue Za Zhi; 2016 Feb; 37(2):238-42. PubMed ID: 26917523
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of a pentavalent rotavirus vaccine in Japan.
Itzler R; O'Brien MA; Yamabe K; Abe M; Dhankhar P
J Med Econ; 2013 Oct; 16(10):1216-27. PubMed ID: 23919721
[TBL] [Abstract][Full Text] [Related]
24. Effects of geographic and economic heterogeneity on rotavirus diarrhea burden and vaccination impact and cost-effectiveness in the Lao People's Democratic Republic.
Rheingans R; Anderson JD; Bagamian KH; Pecenka CJ
Vaccine; 2018 Dec; 36(51):7868-7877. PubMed ID: 30007827
[TBL] [Abstract][Full Text] [Related]
25. Comparative evaluation of the potential impact of rotavirus versus HPV vaccination in GAVI-eligible countries: a preliminary analysis focused on the relative disease burden.
Kim SY; Sweet S; Chang J; Goldie SJ
BMC Infect Dis; 2011 Jun; 11():174. PubMed ID: 21679420
[TBL] [Abstract][Full Text] [Related]
26. Economic impact of a rotavirus vaccination program in Mexico.
Constenla D; Velázquez FR; Rheingans RD; Antil L; Cervantes Y
Rev Panam Salud Publica; 2009 Jun; 25(6):481-90. PubMed ID: 19695142
[TBL] [Abstract][Full Text] [Related]
27. Cost effectiveness evaluation of a rotavirus vaccination program in Argentina.
Martí SG; Alcaraz A; Valanzasca P; McMullen M; Standaert B; Garay U; Lepetic A; Gomez J
Vaccine; 2015 Oct; 33(42):5684-5690. PubMed ID: 26303875
[TBL] [Abstract][Full Text] [Related]
28. Introducing rotavirus vaccine in eight sub-Saharan African countries: a cost-benefit analysis.
Okafor CE; Ekwunife OI
Lancet Glob Health; 2021 Aug; 9(8):e1088-e1100. PubMed ID: 34297961
[TBL] [Abstract][Full Text] [Related]
29. Economic analysis for evidence-based policy-making on a national immunization program: a case of rotavirus vaccine in Thailand.
Muangchana C; Riewpaiboon A; Jiamsiri S; Thamapornpilas P; Warinsatian P
Vaccine; 2012 Apr; 30(18):2839-47. PubMed ID: 22387220
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness analysis of introducing rotavirus vaccine into immunization program in Zhejiang province, China: A decision tree-Markov model study.
Lv H; Chen F; Wang Y; Chen Y; Hu Y
Hum Vaccin Immunother; 2023 Aug; 19(2):2217075. PubMed ID: 37455405
[TBL] [Abstract][Full Text] [Related]
31. Rotavirus vaccination: cost-effectiveness and impact on child mortality in developing countries.
Atherly D; Dreibelbis R; Parashar UD; Levin C; Wecker J; Rheingans RD
J Infect Dis; 2009 Nov; 200 Suppl 1():S28-38. PubMed ID: 19817610
[TBL] [Abstract][Full Text] [Related]
32. Potential cost-effectiveness of vaccination for rotavirus gastroenteritis in eight Latin American and Caribbean countries.
Rheingans RD; Constenla D; Antil L; Innis BL; Breuer T
Rev Panam Salud Publica; 2007 Apr; 21(4):205-16. PubMed ID: 17612464
[TBL] [Abstract][Full Text] [Related]
33. Impact and cost-effectiveness of rotavirus vaccination in Niger: a modelling study evaluating alternative rotavirus vaccines.
Debellut F; Tang K; Clark A; Pecenka C; Assao B; Guindo O; Grais RF; Isanaka S
BMJ Open; 2022 Oct; 12(10):e061673. PubMed ID: 36198460
[TBL] [Abstract][Full Text] [Related]
34. Cost-Effectiveness of Rotavirus Vaccination in France-Accounting for Indirect Protection.
Yamin D; Atkins KE; Remy V; Galvani AP
Value Health; 2016; 19(6):811-819. PubMed ID: 27712709
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of rotavirus vaccination: exploring caregiver(s) and "no medical care'' disease impact in Belgium.
Bilcke J; Van Damme P; Beutels P
Med Decis Making; 2009; 29(1):33-50. PubMed ID: 18948433
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of rotavirus vaccination as part of the national immunization program for Thai children.
Chotivitayatarakorn P; Chotivitayatarakorn P; Poovorawan Y
Southeast Asian J Trop Med Public Health; 2010 Jan; 41(1):114-25. PubMed ID: 20578490
[TBL] [Abstract][Full Text] [Related]
37. Estimated impact and cost-effectiveness of rotavirus vaccination in Senegal: A country-led analysis.
Diop A; Atherly D; Faye A; Lamine Sall F; Clark AD; Nadiel L; Yade B; Ndiaye M; Fafa Cissé M; Ba M
Vaccine; 2015 May; 33 Suppl 1():A119-25. PubMed ID: 25919151
[TBL] [Abstract][Full Text] [Related]
38. TRIVAC decision-support model for evaluating the cost-effectiveness of Haemophilus influenzae type b, pneumococcal and rotavirus vaccination.
Clark A; Jauregui B; Griffiths U; Janusz CB; Bolaños-Sierra B; Hajjeh R; Andrus JK; Sanderson C
Vaccine; 2013 Jul; 31 Suppl 3():C19-29. PubMed ID: 23777686
[TBL] [Abstract][Full Text] [Related]
39. Budget impact and cost-effectiveness of including a pentavalent rotavirus vaccine in the New Zealand childhood immunization schedule.
Milne RJ; Grimwood K
Value Health; 2009 Sep; 12(6):888-98. PubMed ID: 19490550
[TBL] [Abstract][Full Text] [Related]
40. Economic Evaluation of Human Rotavirus Vaccine in Thailand.
Saokaew S; Prasitsuebsai W; Bibera GL; Kengkla K; Zhang XH; Oh KB; Lee C
Infect Dis Ther; 2019 Sep; 8(3):397-415. PubMed ID: 31197662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
